150 related articles for article (PubMed ID: 10415720)
1. Design and synthetic considerations of matrix metalloproteinase inhibitors.
Skotnicki JS; Zask A; Nelson FC; Albright JD; Levin JI
Ann N Y Acad Sci; 1999 Jun; 878():61-72. PubMed ID: 10415720
[TBL] [Abstract][Full Text] [Related]
2. Design strategies for the identification of MMP-13 and Tace inhibitors.
Skotnicki JS; DiGrandi MJ; Levin JI
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
[TBL] [Abstract][Full Text] [Related]
3. Metalloproteinase inhibitors as therapeutics.
Gordon JL; Drummond AH; Galloway WA
Clin Exp Rheumatol; 1993; 11 Suppl 8():S91-4. PubMed ID: 8391953
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase inhibitors: applications in oncology.
Yip D; Ahmad A; Karapetis CS; Hawkins CA; Harper PG
Invest New Drugs; 1999; 17(4):387-99. PubMed ID: 10759405
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase inhibitors: present achievements and future prospects.
Denis LJ; Verweij J
Invest New Drugs; 1997; 15(3):175-85. PubMed ID: 9387040
[TBL] [Abstract][Full Text] [Related]
6. The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis.
Bigg HF; Rowan AD
Curr Opin Pharmacol; 2001 Jun; 1(3):314-20. PubMed ID: 11712757
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases involvement in pathologic conditions.
Amălinei C; Căruntu ID; Giuşcă SE; Bălan RA
Rom J Morphol Embryol; 2010; 51(2):215-28. PubMed ID: 20495735
[TBL] [Abstract][Full Text] [Related]
8. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?
Murphy G; Nagase H
Nat Clin Pract Rheumatol; 2008 Mar; 4(3):128-35. PubMed ID: 18253109
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases. Novel targets for directed cancer therapy.
Yu AE; Hewitt RE; Connor EW; Stetler-Stevenson WG
Drugs Aging; 1997 Sep; 11(3):229-44. PubMed ID: 9303281
[TBL] [Abstract][Full Text] [Related]
10. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms.
Golub LM; Lee HM; Ryan ME; Giannobile WV; Payne J; Sorsa T
Adv Dent Res; 1998 Nov; 12(2):12-26. PubMed ID: 9972117
[TBL] [Abstract][Full Text] [Related]
11. Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis.
Shaw T; Nixon JS; Bottomley KM
Expert Opin Investig Drugs; 2000 Jul; 9(7):1469-78. PubMed ID: 11060752
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases and their inhibition in periodontal treatment.
Ryan ME; Ramamurthy S; Golub LM
Curr Opin Periodontol; 1996; 3():85-96. PubMed ID: 8624573
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
[TBL] [Abstract][Full Text] [Related]
14. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
Zucker S; Cao J; Chen WT
Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
[TBL] [Abstract][Full Text] [Related]
15. Hydroxamic acids as matrix metalloproteinase inhibitors.
Verma RP
Exp Suppl; 2012; 103():137-76. PubMed ID: 22642192
[TBL] [Abstract][Full Text] [Related]
16. [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects].
Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
Ann Biol Clin (Paris); 2003; 61(2):147-58. PubMed ID: 12702469
[TBL] [Abstract][Full Text] [Related]
17. Connective tissue degradation in health and periodontal disease and the roles of matrix metalloproteinases and their natural inhibitors.
Reynolds JJ; Hembry RM; Meikle MC
Adv Dent Res; 1994 Jul; 8(2):312-9. PubMed ID: 7865092
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
Almstead NG; Bradley RS; Pikul S; De B; Natchus MG; Taiwo YO; Gu F; Williams LE; Hynd BA; Janusz MJ; Dunaway CM; Mieling GE
J Med Chem; 1999 Nov; 42(22):4547-62. PubMed ID: 10579818
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A.
Ikejiri M; Bernardo MM; Meroueh SO; Brown S; Chang M; Fridman R; Mobashery S
J Org Chem; 2005 Jul; 70(14):5709-12. PubMed ID: 15989356
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
Yang JS; Lin CW; Su SC; Yang SF
Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
